General Information of DTT (ID: TTT3ZC9)

DTT Name Human immunodeficiency virus Tat protein (HIV tat) DTT Info
Gene Name HIV tat

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
1 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [1]
------------------------------------------------------------------------------------
3 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
ALX-40-4C DMV934L Human immunodeficiency virus infection 1C62 Phase 2 [2]
Ro-24-7429 DMA2UYE Human immunodeficiency virus infection 1C62 Phase 2 [3]
Anti-HIV ribozyme therapy DMQZJ3B Human immunodeficiency virus infection 1C62 Phase 1/2 [4]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
EM-2487 DMG9R8E Human immunodeficiency virus infection 1C62 Terminated [5]
------------------------------------------------------------------------------------
2 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
CGP 40336A DMEA5BZ Discovery agent N.A. Investigative [6]
Durhamycin A DM29PTO Discovery agent N.A. Investigative [7]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Docking studies reveal a selective binding of D-penicillamine to the transactivator protein of human immunodeficiency virus type 1. FEBS Lett. 2002 Apr 10;516(1-3):43-6.
2 Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J Virol. 1996 May;70(5):2825-31.
3 A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis. 1995 Nov;172(5):1246-52.
4 Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Methods Mol Biol. 2004;252:581-98.
5 EM2487, a novel anti-HIV-1 antibiotic, produced by Streptomyces sp. Mer-2487: taxonomy, fermentation, biological properties, isolation and structure elucidation. J Antibiot (Tokyo). 1999 Nov;52(11):971-82.
6 RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86.
7 Durhamycin A, a potent inhibitor of HIV Tat transactivation. J Nat Prod. 2002 Aug;65(8):1091-5.